Sands Capital Management Lowers stake in Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corp (EW) : Sands Capital Management reduced its stake in Edwards Lifesciences Corp by 5.44% during the most recent quarter end. The investment management company now holds a total of 9,619,255 shares of Edwards Lifesciences Corp which is valued at $1,092,747,368 after selling 553,733 shares in Edwards Lifesciences Corp , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Edwards Lifesciences Corp makes up approximately 3.07% of Sands Capital Management’s portfolio.

Other Hedge Funds, Including , Visium Asset Management Lp sold out all of its stake in EW during the most recent quarter. The investment firm sold 45,926 shares of EW which is valued $5,217,194.Clifford Swan Investment Counsel reduced its stake in EW by selling 8,604 shares or 5.73% in the most recent quarter. The Hedge Fund company now holds 141,631 shares of EW which is valued at $16,089,282. Edwards Lifesciences Corp makes up approx 1.08% of Clifford Swan Investment Counsel’s portfolio.Endurance Wealth Management boosted its stake in EW in the latest quarter, The investment management firm added 860 additional shares and now holds a total of 80,758 shares of Edwards Lifesciences Corp which is valued at $9,144,228. Edwards Lifesciences Corp makes up approx 1.65% of Endurance Wealth Management’s portfolio.Her Majesty The Queen In Right Of The Province Of Alberta… boosted its stake in EW in the latest quarter, The investment management firm added 6,800 additional shares and now holds a total of 194,500 shares of Edwards Lifesciences Corp which is valued at $22,048,520. Edwards Lifesciences Corp makes up approx 0.28% of Her Majesty The Queen In Right Of The Province Of Alberta…’s portfolio. Insight Capital Research Management Inc added EW to its portfolio by purchasing 24,604 company shares during the most recent quarter which is valued at $2,815,682. Edwards Lifesciences Corp makes up approx 0.94% of Insight Capital Research Management Inc’s portfolio.

Edwards Lifesciences Corp opened for trading at $115.19 and hit $116.86 on the upside on Monday, eventually ending the session at $116.1, with a gain of 0.73% or 0.84 points. The heightened volatility saw the trading volume jump to 7,10,004 shares. Company has a market cap of $24,715 M.

On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.

Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 115 from a previous price target of $100 .Company shares were Reiterated by Canaccord Genuity on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 140 from a previous price target of $132 .Company shares were Reiterated by Leerink Partners on Jul 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 130 from a previous price target of $125 .

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Leave a Reply

Edwards Lifesciences Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Edwards Lifesciences Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.